A recent study in the “Journal of Clinical Medicine” explored the long-term effects on sleep and circadian rhythms in COVID-19 survivors who experienced acute respiratory distress syndrome (ARDS). Findings revealed that a year after hospital discharge, over 91% of these patients suffered poor sleep quality, with nearly 59% experiencing insomnia, highlighting the lasting impact of COVID-19 on sleep health.
PharmaTher and Vitruvias Enter Into Collaboration Agreement for Commercialization of KETARX™ (racemic ketamine) in the U.S. | Psychedelic Invest
PharmaTher Holdings Ltd. (OTCQB: PHRRF / CSE: PHRM), a commercial-focused specialty pharmaceutical company, is pleased to announce it has entered into a collaboration agreement with
June 20, 2023